Introduction & Pathophysiology

• Autosomal recessive hemoglobinopathy caused by point mutation (A-T) at sixth codon of $\beta$-globin gene (chromosome 11).
• Amino acid substitution: valine replaces glutamic acid.
• Deoxygenated HbS polymerizes, dictating cellular alterations and rigid, sickled red blood cell (RBC) forms.
• Central event: Vaso-occlusion inducing microvascular ischemia-reperfusion injury.
• Multifactorial pathogenesis involves hemolysis-associated nitric oxide depletion, chronic inflammation, oxidative stress, impaired fibrinolysis, hyperviscosity, and platelet/leukocyte activation.
• Acute crises manifest with severe hematological, infectious, and vaso-occlusive presentations demanding rapid intervention.

Vaso-Occlusive Event (VOE) / Pain Crisis

Pathogenesis & Clinical Presentation

• Cardinal clinical feature; unremitting discomfort.
• Initiated by blood flow disruption in microvasculature via sickled RBCs and cellular elements, inducing tissue ischemia.
• Common sites: Chest, abdomen, extremities, long bones, sternum, ribs, spine, pelvis.
• Dactylitis (hand-foot syndrome): Symmetric/unilateral painful swelling of hands/feet; common in children <3 years.
• Precipitating triggers: Physical stress, infection, dehydration, hypoxia, acidosis, cold exposure, prolonged swimming.
• Incidence: Average 0.8 events/year prompting medical evaluation in SCD-SS.
• Risk factors: High baseline hemoglobin, low hemoglobin F, nocturnal hypoxemia, asthma.

Differentiating Bone Infarction vs. Osteomyelitis

Phases of Sickle Cell Pain

Acute Management Protocol

Home Management

• Initiate nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen) and/or acetaminophen.
• Add oral opioids for escalating pain (codeine for mild; oxycodone/hydrocodone/morphine for moderate).
• Supportive measures: Heating pad, fluids, stool softeners/laxatives (prevent opioid constipation).

Emergency Department / Acute Care

• Rapid triage and administration of analgesics.
• Administer IV ketorolac tromethamine (NSAID) and IV opioids for severe pain.
• Maintain euvolemia; use IV normal saline bolus strictly for identified dehydration/decreased oral intake.
• Avoid aggressive IV hydration unless dehydrated; does not relieve pain.

Inpatient Management

• Scheduled IV opioids; avoid "as-needed" dosing.
• Patient-controlled analgesia (PCA) pump for inadequately controlled pain.
• Adjuvant therapies: Long-acting sustained-release morphine.
• Supportive care: Incentive spirometry (prevents Acute Chest Syndrome), bowel regimen, antihistamines for pruritus, serial compression devices/LMWH for VTE prophylaxis (age $\ge$ 12).
• Transition to oral NSAIDs and opioids upon improvement.
• Investigational: Recombinant ADAMTS13, IV immunoglobulin, inhaled nitrous oxide.
• Preventive: Crizanlizumab (anti-P-selectin antibody).

Acute Chest Syndrome (ACS)

Etiology & Risk Factors

• Leading cause of death; second most common cause of hospitalization.
• Causes: Infection (Mycoplasma, Chlamydia, S. pneumoniae, Parvovirus B19), fat embolization from infarcted marrow, hypoventilation, iatrogenic overhydration.
• Frequent preceding event: Systemic opioid treatment for VOE resulting in hypoventilation.
• Incidence: Peak in 2- to 5-year-olds (25 events/100 patient-years).
• Risk factors: Asthma, high hemoglobin, elevated WBC count.

Clinical & Laboratory Findings

• Definition: New pulmonary radiodensity accompanied by fever, chest pain, tachypnea, cough, hypoxemia, wheezing.
• Rapid progression from simple infiltrate to extensive bilateral consolidation and pleural effusion.
• Fat embolism syndrome features: Rapid respiratory distress, altered mental status, petechial rash.
• Laboratory: Elevated WBC, sudden hemoglobin drop (1.5 g/dL below baseline), subsequent thrombocytosis.

Management Strategy

Respiratory & Hemodynamic Support

• Continuous pulse oximetry; frequent respiratory assessments.
• Supplemental oxygen for hypoxia (drop in pulse oximetry by 4% over baseline, or values <90%).
• IV/oral fluids kept at maintenance; strict avoidance of overhydration.
• Regular incentive spirometry (10-12 breaths every 2 hours).
• Chest physiotherapy and mechanical ventilation as needed.

Pharmacotherapy & Transfusion

• Empirical Antibiotics: Broad-spectrum IV cephalosporin combined with oral macrolide (erythromycin/azithromycin) targeting atypical bacteria.
• Bronchodilators: Indicated for reactive airway disease history or active wheezing.
• Corticosteroids: Beneficial for severe ACS/asthma component; caution required due to rebound VOE pain upon discontinuation.
• Pain control: Optimize analgesia to prevent splinting; avoid oversedation causing hypoventilation.
• Transfusion:
  • Simple RBC transfusion (10-15 cm3/kg); target maximum post-transfusion Hb $\le$ 10 g/dL.
  • Exchange transfusion: Indicated for severe hypoxemia, respiratory distress, or failure to improve with simple transfusion.

Neurological Complications (Acute Overt Stroke)

Pathophysiology & Presentation

• Predominantly ischemic in children; hemorrhagic stroke incidence increases in older children/adults.
• Pathogenesis: Chronic endothelial injury by sickled RBCs causes intimal proliferation and luminal narrowing.
• Primary locations: Distal internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA).
• Infarction mechanism: In situ occlusion, distal embolization, or perfusional deficit in watershed zones.
• Clinical presentation: Acute focal neurological deficit lasting >24 hours, hemiparesis, slurred speech, altered consciousness, seizures.
• Differential diagnosis: Posterior reversible encephalopathy syndrome (PRES), cerebral venous thrombosis, fat embolism syndrome.

Diagnostic Imaging

• Emergent evaluation by neurology/hematology.
• Non-contrast Head CT: Rapidly excludes intracranial hemorrhage.
• Brain MRI (diffusion-weighted): Highly sensitive for early ischemia (abnormal within 1 hour).
• MR Angiography (MRA) / MR Venography: Identifies cerebral vasculopathy or venous thrombosis; secondary to acute stabilization.

Acute Management

• Maintain oxygen saturation >96%.
• Rapid simple blood transfusion within 2 hours of presentation.
  • Goal: Elevate hemoglobin to maximum 10 g/dL. Strictly avoid exceeding 10 g/dL to prevent hyperviscosity-induced cerebral ischemia.
• Exchange transfusion (manual or automated erythrocytapheresis) must follow promptly to reduce HbS percentage to <30%.
• Supportive therapy: Avoid hypotension; maintain euthermia.

Splenic Sequestration Crisis

Pathogenesis & Clinical Features

• Life-threatening complication; primarily affects infants and children aged 6 months to 2 years (SCD-SS).
• Can occur throughout adulthood in SCD-SC and SCD-S$\beta^+$-thalassemia.
• Pathophysiology: Massive pooling and trapping of blood within the spleen.
• Triggers: Spontaneous, fever, bacteremia, viral infections (e.g., Parvovirus B19).
• Presentation: Rapid splenic enlargement, left-sided abdominal pain, pallor, fatigue.
• Hemodynamic compromise: Precipitous hemoglobin decline (often <3 g/dL), hypovolemic shock, death.
• Laboratory: Marked reticulocytosis, nucleated RBCs, decreasing WBC and platelet counts.

Management & Prevention

• Continuous cardiovascular monitoring.
• Fluid resuscitation: Isotonic normal saline bolus (10-20 cm3/kg) for hypovolemia.
• RBC Transfusion:
  • Small aliquots (5 mL/kg) administered carefully.
  • Goal: Target post-transfusion Hb 8 g/dL to prevent hypovolemia.
  • Caution: Transfusion aborts RBC trapping; sequestered cells release back into circulation (autotransfusion). High transfusion volumes risk severe hyperviscosity syndrome.
• Secondary Prevention:
  • Recurrence rate 65%, usually within 6 months.
  • Prophylactic splenectomy post-recovery is the definitive preventive strategy.
  • Chronic transfusion therapy utilized temporarily in children <2 years to delay splenectomy.

Transient Pure Red Cell Aplasia (Aplastic Crisis)

Etiology & Presentation

• Temporary cessation of RBC production persisting 7-14 days.
• Pathogenesis: Almost invariably triggered by Human Parvovirus B19 infection. Virus directly infects Colony-Forming Unit-Erythroid progenitors, arresting maturation.
• Presentation: Gradual onset of profound anemia; fever.
• Laboratory: Severe reticulocytopenia; sharp decrease in marrow nucleated RBCs. WBC and platelet counts unaffected.
• Associated complications: Pain, splenic sequestration, ACS, stroke, glomerulonephritis.
• Diagnosis: Parvovirus PCR assay strictly superior to IgM/IgG serology.

Management Protocol

• Spontaneous recovery heralded by nucleated RBC appearance and subsequent robust reticulocytosis.
• Hemodynamic monitoring.
• Conservative RBC transfusion indicated only for hemodynamic instability or concurrent severe illness.
  • Target post-transfusion hemoglobin maximum 9-10 g/dL.
• Strict isolation precautions: Highly contagious. Risk of nosocomial spread and danger to pregnant caregivers (hydrops fetalis).
• Monitor siblings with SCD via CBC, reticulocyte count, and Parvovirus PCR.

Priapism

Classification & Pathophysiology

• Unwanted, sustained, painful penile erection.
• Mean onset age 15 years; affects males across all sickle genotypes.
• Pathophysiology: Low-flow state; venous stasis caused by RBC sickling in corpora cavernosa.
• Patterns:
  • Prolonged: Lasting >4 hours.
  • Stuttering: Brief episodes <3 hours; cluster frequently and herald prolonged events.
• Complications: Irreversible ischemic injury, high risk of erectile dysfunction (impotence).

Acute Management

Conservative & Pharmacologic

• Home interventions: Warm baths, oral analgesics, increased oral hydration, brief aerobic exercise, oral pseudoephedrine.
• Emergency evaluation mandated for episodes lasting >2 hours.
• ER treatment: Intravenous hydration, parenteral opioid analgesia.
• Investigational: Inhaled nitrous oxide (maximum 60%) for rapid detumescence.

Surgical & Transfusion

• Prolonged episodes (>4 hours) require urgent urological consultation.
• Aspiration of blood from corpus cavernosum.
• Irrigation with dilute epinephrine (1:1,000,000) or alpha-adrenergic agent (phenylephrine) to induce sustained detumescence.
• Simple or exchange blood transfusion utilized if surgical management fails; however, detumescence may delay up to 24 hours post-transfusion, risking acute neurological events.

Fever and Serious Bacterial Infections (Bacteremia)

Pathogenesis (Functional Asplenia)

• Medical emergency with high mortality rate.
• Splenic dysfunction evident by 6 months; complete functional asplenia by 5 years.
• Profound susceptibility to encapsulated organisms: Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis, and Salmonella spp..

Clinical Risk Factors for Acute Complications in Febrile Children

Acute Management

• Rapid clinical evaluation, CBC with differential, reticulocyte count, and multiple blood cultures.
• Chest radiograph indicated for all children <3 years or older children with respiratory symptoms.
• Lumbar puncture for young infants (<2-3 months) or older children displaying meningeal signs.
• Prompt initiation of broad-spectrum IV antimicrobials (e.g., ceftriaxone, ampicillin, or third-generation cephalosporin) targeting encapsulated pathogens.
• Hospital admission for 24 hours is standard for IV antimicrobial therapy and observation.
• Outpatient management considered only for lowest-risk children post-IV ceftriaxone dose, ensuring continuous blood culture monitoring and reliable follow-up.
• Note: Patients receiving ceftriaxone must be monitored for rapid, life-threatening immune hemolysis.
• If Salmonella or S. aureus bacteremia develops, perform MRI to evaluate for osteomyelitis.